Planned Interim Analysis of a Phase 2 Investigator-Initiated Trial of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel

We report here our planned interim analysis of 15 patients (pts) enrolled in a phase 2 study of anakinra to prevent CRS and ICANS after lisocabtagene maraleucel (liso-cel; NCT04359784).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Emily C. Liang, Aya Albittar, Andrew J. Portuguese, Jennifer J. Huang, Natalie Wuliji, Qian Wu, Joseph De Los Reyes, Nikki Pin, Aiko Torkelson, Delaney R. Kirchmeier, Abigail Chutnik, Barbara S. Pender, Sylvain Simon, Tony Chour, Evan W. Newell, Mazyar Sh Tags: 233 Source Type: research